LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Ma...( BURLINGTON Mass. Dec. 21 /- LeMai...)

BURLINGTON, Mass., Dec. 21 /PRNewswire-FirstCall/ -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of peripheral vascular devices and implants, yesterday acquired Biomateriali S.r.l., a privately held Italian vascular graft manufacturer, for euro 1.8 million in cash, the assumption of euro 0.8 million in intercompany liabilities, and contingent liabilities of euro 1.0 - euro 1.5 million. The acquisition was structured as a stock purchase.

Key attributes of Biomateriali:

-- Biomateriali designs, manufactures, and markets straight and bifurcated

polyester arterial prostheses. Polyester vascular grafts are used in a

variety of arterial replacement and repair surgeries, predominantly

open abdominal aortic aneurysm ("AAA") repair. Biomateriali has been

manufacturing these prostheses under the "Albograft" brand for over 10

years.

-- Biomateriali's net revenues were approximately euro 2.1 million in the

last twelve months. Depending upon the amount of contingent liabilities

eventually paid, the acquisition was executed at a 1.7x - 2.0x multiple

of LTM revenues.

-- Biomateriali's Albograft implants are CE-marked and distributed

exclusively by Edwards Lifesciences throughout Europe and in select

international markets. Biomateriali also supplies straight polyester

conduit grafts for cardiovascular surgery on an OEM basis to the Sorin

Group.

-- Biomateriali has 30 employees in a 15,000 square foot manufacturing

facility in Brindisi, Italy.

"The polyester vascular graft market continues to represent one of the larger markets in vascular surgery," said David B. Roberts, President of L
'/>"/>